Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

Dalhousie University

$25,000.00

Nickel-Catalyzed Synthesis and N-Arylation of Biologically Active Sulfonamides

EF 2019-20

Résumé
The majority of pharmaceutical compounds derive their beneficial properties from the presence of nitrogen-containing functional groups, including the sulfonamide structural motif. This collaborative research project will seek to exploit recent expertise in sustainable catalysis developed by the applicant's research group, in addressing specific unmet challenges faced by the industrial partner (ParazaPharma Inc., Montreal, QC) with regard to the targeted synthesis and/or modification of biologically active sulfonamide compounds within proprietary active pharmaceutical ingredients. In particular, the industrial partner requires mild routes to biologically active sulfonamides, as well as the N-functionalization of such compounds, ideally exploiting cheap and abundant reagents (e.g., amines, (hetero)aryl chlorides), and making use of Earth abundant catalysts (rather than precious metal catalysts). Once developed, these synthetic protocols can be exploited directly by scientists at ParazaPharma Inc. in proprietary API synthesis/drug development. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Nova Scotia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
542827-2019
Name nom
Stradiotto, Mark
Department département
Chemistry
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
500
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Manufacturing processes and products
Area of application fr
Procédés et produits industriels
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
Nickel-Catalyzed Synthesis and N-Arylation of Biologically Active Sulfonamides
Keyword
NSERC
Application summary
The majority of pharmaceutical compounds derive their beneficial properties from the presence of nitrogen-containing functional groups, including the sulfonamide structural motif. This collaborative research project will seek to exploit recent expertise in sustainable catalysis developed by the applicant's research group, in addressing specific unmet challenges faced by the industrial partner (ParazaPharma Inc., Montreal, QC) with regard to the targeted synthesis and/or modification of biologically active sulfonamide compounds within proprietary active pharmaceutical ingredients. In particular, the industrial partner requires mild routes to biologically active sulfonamides, as well as the N-functionalization of such compounds, ideally exploiting cheap and abundant reagents (e.g., amines, (hetero)aryl chlorides), and making use of Earth abundant catalysts (rather than precious metal catalysts). Once developed, these synthetic protocols can be exploited directly by scientists at ParazaPharma Inc. in proprietary API synthesis/drug development. Success in this project will greatly accelerate the industrial partner's drug development program, thereby leading to more rapid identification of novel therapies to the benefit of all Canadians.